MX2010014230A - Composiciones que contienen pirido [2,3-d] pirimidinas sustituidas con metilmorfolina y proceso relacionado. - Google Patents

Composiciones que contienen pirido [2,3-d] pirimidinas sustituidas con metilmorfolina y proceso relacionado.

Info

Publication number
MX2010014230A
MX2010014230A MX2010014230A MX2010014230A MX2010014230A MX 2010014230 A MX2010014230 A MX 2010014230A MX 2010014230 A MX2010014230 A MX 2010014230A MX 2010014230 A MX2010014230 A MX 2010014230A MX 2010014230 A MX2010014230 A MX 2010014230A
Authority
MX
Mexico
Prior art keywords
methylmorpholin
subsituted
pyrido
pyrimidines
compositions
Prior art date
Application number
MX2010014230A
Other languages
English (en)
Inventor
Powell Lyn
Blade Helen
Huw Chrchill Gwydion
Charlotte Currie Angela
Charles Dobson Benjamin
Samuel Hynes Peter
Neal Kenworthy Martin
Anthony Raw Steven
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2010014230A publication Critical patent/MX2010014230A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe un proceso para la preparación de un compuesto de la fórmula 1, el uso de tal proceso en la preparación de un compuesto de la fórmula 5 o una sal de fosfato, sulfato, hidrógeno-sulfato, malato, citrato, tartrato o fumarato del mismo, y el uso de la sal de fumarato en una composición para el uso en terapia..
MX2010014230A 2008-06-20 2009-06-18 Composiciones que contienen pirido [2,3-d] pirimidinas sustituidas con metilmorfolina y proceso relacionado. MX2010014230A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7418808P 2008-06-20 2008-06-20
US15235009P 2009-02-13 2009-02-13
PCT/GB2009/050695 WO2009153597A2 (en) 2008-06-20 2009-06-18 Composition and process - 356

Publications (1)

Publication Number Publication Date
MX2010014230A true MX2010014230A (es) 2011-03-29

Family

ID=41051136

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010014230A MX2010014230A (es) 2008-06-20 2009-06-18 Composiciones que contienen pirido [2,3-d] pirimidinas sustituidas con metilmorfolina y proceso relacionado.

Country Status (27)

Country Link
US (1) US8198441B2 (es)
EP (1) EP2303875B1 (es)
JP (1) JP5607614B2 (es)
KR (1) KR101668497B1 (es)
CN (1) CN102137860B (es)
AR (1) AR072263A1 (es)
AU (1) AU2009261688B2 (es)
BR (1) BRPI0914912A2 (es)
CA (1) CA2728183C (es)
CL (1) CL2010001488A1 (es)
CO (1) CO6351729A2 (es)
CR (1) CR11859A (es)
DO (1) DOP2010000391A (es)
EA (1) EA019092B1 (es)
EC (1) ECSP10010696A (es)
ES (1) ES2398423T3 (es)
HK (1) HK1155160A1 (es)
IL (1) IL210074A (es)
MX (1) MX2010014230A (es)
MY (1) MY172107A (es)
NI (1) NI201000225A (es)
PE (1) PE20110147A1 (es)
SV (1) SV2010003770A (es)
TW (1) TWI441821B (es)
UY (1) UY31917A (es)
WO (1) WO2009153597A2 (es)
ZA (1) ZA201101861B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2715181A1 (en) * 2008-02-21 2009-08-27 Astrazeneca Ab Combination therapy 238
TWI441824B (zh) 2010-12-16 2014-06-21 Hoffmann La Roche 三環ｐｉ３ｋ抑制劑化合物及其使用方法
CN104803922A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种嘧啶衍生物的制备方法
CN106008559B (zh) * 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
SG11202012447YA (en) 2018-06-15 2021-01-28 Navitor Pharm Inc Rapamycin analogs and uses thereof
IL293549A (en) 2019-12-05 2022-08-01 Anakuria Therapeutics Inc Rapamycin analogs and their uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560685A (en) * 1984-06-18 1985-12-24 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung 2-Piperazino-pteridines useful as antithrombotics and antimetastatics
DE3445298A1 (de) 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
HU229958B1 (hu) 1999-09-07 2015-03-30 Syngenta Participations Ag Herbicid vegyületek, ezeket tartalmazó készítmények, eljárás a vegyületek előállítására, valamint eljárás gyomnövények irtására
WO2001083456A1 (fr) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derives d'heteroaryle condenses
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EP1575951B1 (en) 2002-12-06 2014-06-25 Debiopharm International SA Heterocyclic compounds, methods of making them and their use in therapy
US20050009817A1 (en) 2003-04-30 2005-01-13 Jennifer Savoy Substituted heteroaryls
GB0428475D0 (en) 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
JP2008543888A (ja) 2005-06-24 2008-12-04 ギリアード サイエンシーズ， インコーポレイテッド ピリド（３，２−ｄ）ピリミジン、およびＣ型肝炎を治療するのに有用な医薬組成物
US20070128658A1 (en) * 2005-11-14 2007-06-07 Blackwell Helen E Fluorescent dyes, methods and uses thereof
JP5161102B2 (ja) 2005-11-22 2013-03-13 クドス ファーマシューティカルズ リミテッド ｍＴＯＲ阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体
SI2057156T1 (sl) * 2006-08-23 2017-06-30 Kudos Pharmaceuticals Limited Derivati 2-metilmorfolin pirido-, pirazo- in pirimido-pirimidina kot inhibitorji mTOR
CN101896180A (zh) 2007-10-15 2010-11-24 阿斯利康(瑞典)有限公司 组合059

Also Published As

Publication number Publication date
ES2398423T3 (es) 2013-03-19
EA019092B1 (ru) 2014-01-30
AU2009261688A1 (en) 2009-12-23
WO2009153597A3 (en) 2010-05-06
JP5607614B2 (ja) 2014-10-15
KR101668497B1 (ko) 2016-10-21
BRPI0914912A2 (pt) 2017-06-20
CN102137860A (zh) 2011-07-27
NI201000225A (es) 2011-12-15
IL210074A0 (en) 2011-02-28
CN102137860B (zh) 2013-08-28
HK1155160A1 (en) 2012-05-11
CR11859A (es) 2011-02-25
CL2010001488A1 (es) 2011-07-15
ECSP10010696A (es) 2011-01-31
AU2009261688B2 (en) 2012-07-05
PE20110147A1 (es) 2011-03-26
EP2303875A2 (en) 2011-04-06
ZA201101861B (en) 2011-11-30
MY172107A (en) 2019-11-14
US8198441B2 (en) 2012-06-12
AR072263A1 (es) 2010-08-18
IL210074A (en) 2015-07-30
KR20110027789A (ko) 2011-03-16
WO2009153597A2 (en) 2009-12-23
UY31917A (es) 2010-01-29
TWI441821B (zh) 2014-06-21
TW201012818A (en) 2010-04-01
EA201100063A1 (ru) 2011-10-31
CA2728183A1 (en) 2009-12-23
US20090318434A1 (en) 2009-12-24
DOP2010000391A (es) 2011-01-15
CO6351729A2 (es) 2011-12-20
EP2303875B1 (en) 2012-11-28
SV2010003770A (es) 2011-05-20
CA2728183C (en) 2016-10-25
JP2011524889A (ja) 2011-09-08

Similar Documents

Publication Publication Date Title
MX2010014230A (es) Composiciones que contienen pirido [2,3-d] pirimidinas sustituidas con metilmorfolina y proceso relacionado.
RS20080484A (en) PYRIDINE[3,4-b] PYRAZINONES
MX340533B (es) Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
MX2010009414A (es) Derivados de imidazo-[1,2-b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met.
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
MY149731A (en) Compounds
MX2010007746A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de diana de rapamicina de mamifero quinasa y fosfatidilinositol quinasa y su sintesis.
EP2650293A8 (en) [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
MY187131A (en) Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
MY164274A (en) Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
UA89968C2 (uk) Похідні піроло[3,2-d]-піримідин-4-ону та їх застосування у терапії
MX2009005413A (es) Formas cristalinas del acido zoledronico.
SI2041133T1 (sl) Imidazo (1,2,a)piridin-2-karboksamidni derivati, njihova priprava in njihova uporaba v terapevtiki
MX2013011854A (es) Compuestos de pirazol[3,4-b]piridina tri- y tetraciclica como agentes antineoplasicos.
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
WO2008049855A3 (en) 7-azaindole derivatives as c-met kinase inhibitors
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
MX339302B (es) 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
IL195818A0 (en) Derivatives of 2-benzoyl-imidazopyridines, preparation ,method thereof and use of same in therapeutics
PT1869038E (pt) Compostos de 5,6,7,8-tetra-hidro-imidazo[1,2-a]piridin-2- ilamina substituída e sua utilização para produzir fármacos
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
AU2010275640A8 (en) Benzoquinolizinium salt derivatives as anticancer agents
MX2009006325A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof

Legal Events

Date Code Title Description
FG Grant or registration